NASDAQ:RUBY - Rubius Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $11.20
  • Forecasted Upside: 144.54 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.58
▼ -0.1 (-2.14%)
1 month | 3 months | 12 months
Get New Rubius Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RUBY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RUBY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$11.20
▲ +144.54% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Rubius Therapeutics in the last 3 months. The average price target is $11.20, with a high forecast of $28.00 and a low forecast of $4.00. The average price target represents a 144.54% upside from the last price of $4.58.
Hold
The current consensus among 5 polled investment analysts is to hold stock in Rubius Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/2/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/31/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralHigh
i
8/11/2020HC WainwrightReiterated RatingBuy$28.00High
i
3/13/2020GuggenheimLower Price TargetBuy$23.00 ➝ $11.00High
i
3/13/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$15.00 ➝ $4.00High
i
3/13/2020HC WainwrightLower Price TargetBuy$40.00 ➝ $28.00High
i
Rating by Andrew Fein at HC Wainwright
3/13/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$19.00 ➝ $4.00High
i
Rating by J. Chang at SVB Leerink LLC
1/31/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$9.00Medium
i
11/15/2019HC WainwrightReiterated RatingBuy$40.00High
i
Rating by Andrew Fein at HC Wainwright
9/9/2019Robert W. BairdInitiated CoverageUnderperform$4.00 ➝ $4.00High
i
8/29/2019JPMorgan Chase & Co.Lower Price TargetOverweight$27.00 ➝ $22.00High
i
6/26/2019HC WainwrightInitiated CoverageBuy ➝ Buy$40.00High
i
Rating by A. Fein at HC Wainwright
5/30/2019GuggenheimInitiated CoverageBuy$25.00High
i
12/19/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$37.00 ➝ $34.00High
i
8/13/2018SVB LeerinkInitiated CoverageOutperformHigh
i
Rating by J. Chang at SVB Leerink LLC
8/13/2018Morgan StanleyInitiated CoverageOverweight$37.00High
i
8/13/2018JPMorgan Chase & Co.Initiated CoverageOverweightHigh
i
8/13/2018Jefferies Financial GroupInitiated CoverageBuy$40.00High
i
(Data available from 10/23/2015 forward)
Rubius Therapeutics logo
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. It is also developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. In addition, the company is developing RTX-T1D for treating type 1 diabetes; and RTX-PV for treating pemphigus vulgaris. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $4.58
$4.57
$4.72

50 Day Range

MA: $5.08
$4.61
$5.69

52 Week Range

Now: $4.58
$3.35
$14.44

Volume

7,181 shs

Average Volume

309,539 shs

Market Capitalization

$369.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99